"Noreen Griffin, CEO of Immune Therapeutics. "More importantly, we are making significant progress towards receiving final approval to begin commercialization in Africa. Our recent operating achievements coupled with the ongoing financial support received from our key shareholders, should contribute to a strong second quarter. With our improved financial footing, we are preparing to file for additional opportunities for Lodonal in Africa for the near future," added Ms. Griffin"
News 
Market Data 
Discover 
